Answers are grounded in this paper and cite their sources.
Background: Cirrhosis represents a late stage of progressive hepatic fibrosis with an increased risk of numerous complications and a decreased life expectancy.Spontaneous bacterial peritonitis (SBP) is the most common bacterial infection in cirrhosis patients.It is necessary to recognize SBP early during illness to ensure a good outcome due to a short window period to intervene.Piperacillin-tazobactam is a broadspectrum antibiotic that has activity against many Gram-positive and Gram-negative bacteria.Rifaximin is a virtually unabsorbable antibiotic with a broad-spectrum activity against gram-positive and gram-negative microorganisms within the gastrointestinal tract.It minimizes antimicrobial resistance and adverse events and renders the drug safe in all patients.Intestinal decontamination with rifaximin is an attractive approach for the treatment of patients with cirrhosis with SBP. Materials and Methods:This research was a hospital-based prospective comparative open-label interventional study carried out in the Liver unit of one of the tertiary hospitals in Nepal from July 2019 to June 2020 for the total duration of 1 year.Patients of cirrhosis who were diagnosed with SBP were included.Patients with hepatic encephalopathy, renal impairment (creatinine >3mg/dl), allergy to drugs, already on SBP/HE prophylaxis, presence of HCC were excluded.Diagnostic aspiration of the ascitic fluid of all admitted patients was performed at the time of admission.The patients were allocated into two equal groups randomly.Patients in group 1 received Piperacillin-tazobactam 4.5gm 8 hourly intravenously for five days and Rifaximin 1100mg/day orally in two divided doses for five days.Patients in group 2 received Piperacillintazobactam 4.5gm 8 hourly intravenously for five days.The included patients underwent repeat diagnostic aspiration and blood sample tests on the third day of antibiotic therapy to compare the change of ascitic fluid WBC, PMN cells and peripheral WBC after 48 hours of treatment in both groups.A proforma was used to collect the data from the patients enrolled in the study.Data were entered and analyzed using SPSS version 26 software.Results: A total of 34 patients were enrolled, 17 in each group.Out of 34 patients, 76% were male whereas the mean age of the participants was 51.65(±10.21)years.There was male predominance (76%).Ascitic fluid WBC in group 1 was 1891±988 cells/mm3 on the first day and was 84.7±83.5 cells/mm3 on the third day of the therapy.Reduction in the ascitic fluid WBC was statistically significant in both groups with a p-value of less than 0.001.Moreover, the reduction in ascitic fluid WBC count on the third day was statistically significant in group 1 compared with group 2 with a p-value of 0.02.Ascitic fluid PMN, serum creatinine, and peripheral WBCs were reduced significantly in both groups.Group 1 had a clinically significant reduction (p=0.03,0.02, and 0.001 respectively) of these parameters on the third day than in group 2. Conclusion:In our study, rifaximin plus Piperacillin-tazobactam showed more favorable effects in reducing peripheral WBC, creatinine, ascitic fluid WBC, and duration of hospital stay in the treatment of SBP than Piperacillin-tazobactam only.However, the clinical effects and potential role of rifaximin and combination therapy in the management of SBP need further clarification in further studies due to the smaller number of patients in this study.
No takes yet. Share an insight, caveat, or question.
Pukar Thapa (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: